HBM HOLDINGS-B(02142) subsidiary company signed authorization and cooperation agreement with business partners, to advance a new therapy for treating various diseases involving corticotropin-releasing hormone (CRH).

HBM HOLDINGS-B (02142) announced that its innovative biotechnology company HBM Alpha Therapeutics (HBMAT) has entered into an authorization and collaboration agreement with a business partner to advance a novel therapy for treating a variety of diseases involving corticotropin-releasing hormone (CRH). Under the agreement, the business partner has been granted exclusive rights to develop any pharmaceutical products containing or involving HBM9013 globally (excluding the Greater China region, which includes Mainland China, Taiwan, Hong Kong, and Macau). According to the terms of the agreement, HBMAT is entitled to receive up to a total of $395 million in upfront and potential milestone payments, as well as tiered royalties based on single-digit percentage of net sales during the licensing term. Additionally, HBMAT also has the option to receive warrants to acquire a minority stake in the business partner. HBM Alpha Therapeutics is known for developing antibody therapies for rare genetic diseases such as Congenital Adrenal Hyperplasia (CAH) and Polycystic Ovary Syndrome (PCOS), as well as other endocrine disorders related to abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis regulation and function. Established in Delaware, USA in 2019, HBMAT is a joint venture between HBM Pharmaceuticals and the Boston Children's Hospital, a teaching affiliate of Harvard Medical School. HBM9013/HAT001 is an anti-CRH antibody therapy developed by the group aimed at treating CRH-related diseases, including CAH and others. CAH is a group of autosomal recessive genetic disorders caused by mutations in genes encoding crucial enzymes for adrenal hormone synthesis, leading to serious health consequences. Currently, treatment options for CAH are limited, highlighting a significant unmet medical need for innovative therapies. HBM9013/HAT001 has shown strong preclinical efficacy in reducing CRH-mediated adrenocorticotropic hormone (ACTH) induction and is progressing towards clinical development.